HNRNPH2 (Heterogeneous Nuclear Ribonucleoprotein H2) is a human gene located on the X chromosome (Xq28) that encodes a member of the heterogeneous nuclear ribonucleoprotein H family. This protein plays critical roles in alternative splicing regulation, particularly of neuronal transcripts, and has been implicated in various neurodevelopmental and neurodegenerative disorders. This page covers the gene's normal function, disease associations, expression patterns, molecular mechanisms, and key research findings relevant to neurodegeneration.
| Attribute | Value |
|---|---|
| Gene Symbol | HNRNPH2 |
| Gene Name | Heterogeneous Nuclear Ribonucleoprotein H2 |
| NCBI Gene ID | 3184 |
| UniProt ID | P55795 |
| Aliases | HNRPH2, HPRH2 |
| Chromosomal Location | Xq28 |
| Gene Type | Protein-coding |
| RefSeq Transcript | NM_001010873 |
HNRNPH2 encodes a member of the heterogeneous nuclear ribonucleoprotein H (hnRNP H) family, which are abundant nuclear proteins involved in multiple aspects of RNA processing. The hnRNP H family proteins are characterized by the presence of quasi-RNA recognition motifs (qRRMs) that enable them to bind to G-rich RNA sequences and regulate alternative splicing [1].
The primary functions of HNRNPH2 include:
Alternative Splicing Regulation: HNRNPH2 binds to specific G-rich sequence elements in pre-mRNA to influence the inclusion or exclusion of alternative exons. This is particularly important for neuronal transcripts that often undergo complex alternative splicing patterns to generate protein diversity.
Transcriptional Regulation: HNRNPH2 can interact with RNA polymerase II and influence transcriptional elongation, though this function is less well-characterized.
mRNA Stability and Localization: Through binding to specific mRNA species, HNRNPH2 influences mRNA stability, nuclear export, and subcellular localization.
Neuronal Transcriptome Maintenance: Given the high expression of HNRNPH2 in neuronal tissues, it plays a crucial role in maintaining the proper splicing of transcripts essential for neuronal function, synaptic plasticity, and development.
The HNRNPH2 protein contains several key structural features:
Mutations in HNRNPH2 cause X-linked neurodevelopmental disorders characterized by developmental delay, intellectual disability, seizures, and characteristic dysmorphic features. Female carriers may exhibit milder phenotypes due to X-chromosome inactivation patterns [2].
Clinical Features of HNRNPH2-Related Disorders:
The mechanism involves haploinsufficiency of HNRNPH2, leading to disrupted splicing of critical neuronal transcripts during brain development [3].
While HNRNPH2 is not a classic ALS/FTD causative gene, it participates in RNA metabolism pathways that are central to the pathogenesis of these disorders. Similar to other hnRNP H family members (HNRNPH1, HNRNPH3), HNRNPH2 is involved in processing RNAs encoding proteins critical for neuronal survival [4].
Mechanistic Links to ALS/FTD:
TDP-43 Proteinopathy Interaction: TDP-43 (encoded by TARDBP) is the primary aggregating protein in ALS/FTD. HNRNPH2 interacts with TDP-43 and other RNA-binding proteins in RNA granules. Disruption of these interactions may contribute to disease progression.
C9orf72 Hexanucleotide Repeat Expansion Effects: The C9orf72 repeat expansion, the most common genetic cause of familial ALS/FTD, produces toxic RNA foci that sequester RNA-binding proteins including hnRNP H family members. This may disrupt HNRNPH2 function [5].
Splicing Regulation of ALS/FTD Genes: HNRNPH2 regulates alternative splicing of transcripts important for neuronal function, including those involved in synaptic transmission, cytoskeletal organization, and energy metabolism.
Stress Granule Formation: During cellular stress, HNRNPH2 localizes to stress granules—membrane-less organelles that temporarily store mRNAs. Dysregulation of this process is implicated in ALS pathogenesis [6].
Altered expression of HNRNPH2 has been documented in AD brain tissue, particularly in regions affected by tau pathology. Research from 2024 suggests that HNRNPH2 may play a dual role in AD pathogenesis:
While direct evidence for HNRNPH2 involvement in PD is limited, RNA metabolism dysregulation is a common theme in Parkinsonian disorders. Studies suggest potential connections through:
HNRNPH2 regulates the splicing of numerous neuronal transcripts. Key targets include:
| Target Gene | Function | Splicing Effect |
|---|---|---|
| NRCAM | Cell adhesion | Exon inclusion |
| GRM4 | Glutamate receptor | Exon skipping |
| KCNMA1 | Potassium channel | Alternative splicing |
| CACNA1A | Calcium channel | Mutually exclusive exons |
| DNM1 | Synaptic vesicle trafficking | Exon inclusion |
| MAPT | Tau protein | Alternative splicing |
| APP | Amyloid precursor | Alternative splicing |
| SNCA | Alpha-synuclein | 5'UTR splicing |
| LRRK2 | Leucine-rich repeat kinase | Exon skipping |
| PARKIN | Ubiquitin ligase | Alternative splicing |
HNRNPH2 plays a broader role in neuronal splicing regulation:
Neurotransmission-Related Transcripts:
Synaptic Plasticity Factors:
Cytoskeletal and Axonal Transport:
Apoptosis and Cell Survival:
HNRNPH2 interacts with several proteins relevant to neurodegeneration:
Beyond splicing, HNRNPH2 contributes to mRNA localization:
Dendritic mRNA Transport:
Axonal mRNA Regulation:
Synaptic Translation Control:
HNRNPH2 function is modulated by several signaling pathways:
DNA Damage Response: HNRNPH2 phosphorylation affects its RNA binding properties in response to DNA damage. ATM and ATR kinases can phosphorylate HNRNPH2, altering its splicing function in response to genotoxic stress.
Cellular Stress Response: Stress-activated kinases (p38 MAPK, JNK) alter HNRNPH2 localization to stress granules. This translocation is reversible and depends on the phosphorylation state of HNRNPH2.
mTOR Signaling: Nutritional status influences HNRNPH2-mediated splicing. mTOR inhibition can alter the splicing pattern of HNRNPH2 target transcripts, linking cellular energy status to RNA processing.
AMPK Signaling: Energy depletion activates AMPK, which can modulate HNRNPH2 function through direct phosphorylation or by altering its subcellular localization.
ERK/MAPK Pathway: Growth factor signaling through ERK influences HNRNPH2 alternative splicing of neuronal transcripts, particularly those involved in synaptic plasticity.
HNRNPH2 expression and function are subject to epigenetic control:
Transcriptional Regulation: HNRNPH2 promoter contains binding sites for multiple transcription factors. Epigenetic marks (H3K27ac, H3K4me3) at the promoter correlate with expression levels in neuronal tissues.
m6A RNA Modification: HNRNPH2 binding to mRNA can be modulated by N6-methyladenosine (m6A) modifications. The interplay between HNRNPH2 and m6A readers influences splicing outcomes.
lncRNA Interactions: Long non-coding RNAs can sequester HNRNPH2, affecting its availability for splicing regulation. Several neuronal lncRNAs have been shown to interact with HNRNPH2.
HNRNPH2 is expressed in various tissues with highest expression in:
Expression is highest during embryonic brain development and persists into adulthood, suggesting roles in both development and maintenance of neuronal function.
Pathogenic HNRNPH2 variants include:
X-linked dominant. Males are typically more severely affected than females due to X-chromosome inactivation in females.
High penetrance for neurodevelopmental features. Variable expressivity for neurodegenerative manifestations.
Currently no HNRNPH2-targeted therapies exist. The primary therapeutic approaches under investigation target downstream effects rather than HNRNPH2 itself:
Symptomatic Management:
Several therapeutic strategies are being explored:
ASO Therapy: Antisense oligonucleotides to modulate HNRNPH2 splicing patterns. ASOs can be designed to:
RNA Granule Stabilizers: Small molecules to prevent pathological stress granule formation:
Kinase Inhibitors: Modulate HNRNPH2 phosphorylation status:
Splicing Modulators:
Gene therapy approaches for HNRNPH2-related disorders face significant challenges:
Viral Vector Delivery: AAV vectors can deliver wild-type HNRNPH2, but:
CRISPR-Based Gene Editing: Opportunities include:
RNA Therapeutics:
HNRNPH2 expression levels may serve as biomarkers for:
Diagnostic Biomarkers:
Prognostic Biomarkers:
Therapeutic Response Markers:
Several model systems have been developed to study HNRNPH2 function and disease mechanisms:
Mouse Models:
Zebrafish Models:
Cell Models:
In Vitro Systems:
HNRNPH2 models are used for:
The diagnostic pathway for HNRNPH2-related disorders includes:
Sequencing Approaches:
Copy Number Analysis:
Functional Studies:
Prenatal Testing:
Currently no disease-modifying treatments. Management focuses on:
Variable depending on variant type and location. Missense variants may allow for some functional protein production, while nonsense variants typically cause more severe phenotypes.
Long-term Outcomes:
| Protein | Interaction Type | Relevance to Neurodegeneration |
|---|---|---|
| TDP-43 | Direct binding | ALS/FTD hallmark protein |
| FUS | Complex formation | ALS/FTD RNA granule |
| hnRNP A1/A2B1 | Co-complex | Splicing regulation |
| SRSF1/SRSF2 | Splicing co-factors | Alternative splicing |
| SMN | Complex formation | SMA relevance |
Batra et al. HNRNPH family: structure, functions, and implications for disease. 2016. ↩︎
Piard et al. HNRNPH2 variants in neurodevelopmental disorders. 2018. ↩︎
Kendziora et al. HNRNPH2-related neurodevelopmental disorder. 2020. ↩︎
Saxena et al. RNA granule proteins in ALS. 2021. ↩︎
Nahalka et al. The role of the protein-RNA recognition code in neurodegeneration. 2019. ↩︎
Harada et al. Stress granule dynamics in HNRNPH2-related disease. 2023. ↩︎